Moreover, the knockdown of CBP appears to more strongly affect the amyloid reduction pathways compared to knockdown of EP300, which is especially interesting in light of our previous observation of disease-specific activation of CBP and not EP300 in postmortem AD brains [15]. The gene discussed is EP300; the disease is Alzheimer disease.